1Department of Radiograpy, Shandong First Medical University, Jinan, Shandong, China
2GE Healthcare (China), Beijing, China
3GE Healthcare (Taiwan), Taichung, Taiwan
Presenting Author: Jiali Zhang
Synopsis
Motivation:
Goals:
Approach:
Results:
Preview figure
Full abstract & presentation
The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.
Full abstracts, figures, and presentations for 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public on 13 May 2028.
To request or purchase access, contact the ISMRM Central Office at support@ismrm.org.
1. Siegel RL et al. Colorectal cancer statistics, 2023. CA Cancer J Clin, 2023. doi: 10.3322/caac.21772 [doi]
2. Long-term outcome in patients with a pathological Maas M et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol, 2010. doi: 10.1016/S1470-2045(10)70172-8 [doi]
3. Kalbasi A et al. Radiation and immunotherapy: a synergistic combination. J Clin Invest, 2013. doi: 10.1172/JCI69219 [doi]
4. Lin Z et al. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J ImmunoTher Cancer, 2021. doi: 10.1136/jitc-2021-003554 [doi]
5. Xia F et al. Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH). J Clin Oncol, 2024. doi: 10.1200/JCO.23.02261 [doi]
6. Tian F et al. Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial. Lancet Oncol, 2025. doi: 10.1016/S1470-2045(25)00286-4 [doi]
7. Lord AC et al. Assessment of the 2020 NICE criteria for preoperative radiotherapy in patients with rectal cancer treated by surgery alone in comparison with proven MRI prognostic factors: a retrospective cohort study. Lancet Oncol, 2022. doi: 10.1016/S1470-2045(22)00214-5 [doi]
8. Smith NJ et al. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg, 2008. doi: 10.1002/bjs.5917 [doi]
9. Zhao M et al. An MRI-based scoring system for pretreatment risk stratification in locally advanced rectal cancer. Br J Cancer, 2023. doi: 10.1038/s41416-023-02384-x [doi]
10. Sonal S et al. Molecular basis of extramural vascular invasion (EMVI) in colorectal carcinoma. Ann Surg Oncol, 2022. doi: 10.1245/s10434-022-12212-w [doi]